Farina, Emily A. https://orcid.org/0000-0002-9916-8561
Mourgues-Codern, Catalina
Stimler, Katie
Kenney, Joshua
Saxena, Abhishek https://orcid.org/0000-0001-9825-6693
Mukhtar, Hesham https://orcid.org/0009-0007-5298-4063
Addington, Jean https://orcid.org/0000-0002-8298-0756
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
Cadenhead, Kristin S. https://orcid.org/0000-0002-5952-4605
Cannon, Tyrone D.
Cornblatt, Barbara
Ellman, Lauren
Gold, James
Keshavan, Matcheri
Mathalon, Daniel H. https://orcid.org/0000-0001-6090-4974
Mittal, Vijay A. https://orcid.org/0000-0001-9017-5119
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Schiffman, Jason
Silverstein, Steven M. https://orcid.org/0000-0002-0699-0960
Strauss, Gregory P.
Stone, William S. https://orcid.org/0000-0003-2932-7288
Walker, Elaine F. https://orcid.org/0000-0002-9798-8101
Waltz, James https://orcid.org/0000-0002-9236-3719
Corlett, Philip https://orcid.org/0000-0002-5368-1992
Powers, Albert R. https://orcid.org/0000-0003-3057-5043
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH081984, U01MH081902, U01MH081944, U01MH081902, UO1MH081857, R01 MH112613, R01 MH120091, R01 MH120090, U01MH076989, R01 MH116039, R01 MH112545, R01 MH1120088, U01MH082004, R01 MH112612, R01 MH120092, R01 MH116039, R21 MH119438, U01MH081928, U01MH081988, U01 MH081988, R01 MH120090, R01MH120089, U01MH082022, R01MH120089)
New York Fund for Innovation in Research and Scientific Talent
Article History
Received: 28 April 2025
Accepted: 6 August 2025
First Online: 6 October 2025
Competing interests
: Dr. Woods reports that he has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted a US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He is a consultant to and is a partner and owns stock in NW PharmaTech. Philip Corlett is cofounder and board member and holds equity in Tetricus Labs, a Computational Psychiatry company. They did not fund this work. James Gold receives royalty payments from Vera Sci for the Brief Assessment of Cognition in Schizophrenia. The remaining authors declare no competing interests.